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Original StudieS
Objective: rotavirus (rV) gastroenteritis is a notifiable disease in germany. 
the reports to the authorities contain few data concerning the severity of 
disease. the aims of this study were to determine incidence and outcome of 
very severe cases of rV disease.
Methods: Cases of very severe rV disease were collected by the german 
Paediatric Surveillance unit for rare diseases (erhebungseinheit für sel-
tene pädiatrische erkrankungen in deutschland) using anonymous ques-
tionnaires based on hospitalized patients between april 2009 and March 
2011. inclusion criteria were detection of rV antigen in feces, patient aged 
0–16 years and 1 or more of the following criteria: intensive care treatment, 
hypernatremia or hyponatremia (>155 mmol/l or <125 mmol/l), clinical 
signs of encephalopathy (somnolence, seizures, apnea) and rV-associated 
death.
Results: during 2 years, 130 cases of very severe rV disease were reported, 
101 of 130 were verified. Seventeen patients had nosocomial infection, of 
whom 14 were neonates in intensive care. among those, 12 infants had 
verified or suspected necrotizing enterocolitis. eighty-four community-
acquired cases were reported, median age was 10.5 months (0–108 months). 
the median hospital stay was 6 days, and 48 patients needed intensive care 
treatment. among children less than 5 years of age, the yearly incidence 
of community-acquired very severe rV disease was 1.2 of 100,000 (95% 
confidence interval: 0.9–1.4/100,000). a total of 26 of 84 and 10 of 84 
patients had severe hypernatremia or hyponatremia, respectively, and 58 
of 84 patients had signs of encephalopathy. three deaths were reported (1 
nosocomial and 2 community acquired).
Conclusions: rV infection in germany can have a life-threatening course. 
a substantial number are nosocomial infections.
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Rotavirus (rV) is the most common cause of gastroenteritis (ge) in children in germany1 and worldwide.2 it is estimated 
that in a global setting, rV disease annually causes about 530,000 
deaths in children less than 5 years of age.3 However, in industrial-
ized countries, rV ge is usually a mild and self-limiting disease. 
nevertheless, it is estimated that in the european union more than 
87,000 hospitalizations and 231 deaths per year are attributed to 
rV in children less than 5 years of age.4 With an estimated annual 
3.6 million cases of rV ge in children less than 5 years of age in 
the european union, rV causes a heavy burden on society and the 
healthcare system.4 Since 2001, acute rV disease with either diar-
rhea and/or vomiting in germany is to be reported to the robert 
Koch institute (Berlin, germany), the german federal institution 
responsible for disease control and prevention. However, due to 
underreporting, the true number of cases is probably 5–10 times 
higher than the reported cases.5
the 2 available vaccines against rV are safe and effective.6–8 
in 2009, the World Health Organization recommended global use 
of rV vaccines.9 rV immunization is not part of the national vac-
cination program in germany but is under consideration by the 
german Standing Committee on Vaccination.1 in the absence of a 
national recommendation for rV vaccination, some individual fed-
eral states have still recommended rV vaccination. the rV vaccine 
is thus used on a limited level in germany.
Very severe courses of rV infections associated with clini-
cal features such as encephalopathy, severe electrolyte disturbance, 
intensive care treatment and death have been described.10,11 infor-
mation on very severe rV disease (vsrVd) is primarily based on 
case reports or retrospective analyses, whereas prospectively col-
lected data are lacking. especially, prospective studies to query the 
vsrVd are not available.
this study aimed to prospectively detect all vsrVd in 
children younger than 17 years in germany in a 2-year period, to 
gather demographic and incidence data as well as details about 
each individual case. the data could help to better understand the 
virulent properties of rV and could inform decision on a national 
rV vaccine recommendation.
METHODS
Prospective data collection was coordinated by the well-
established german Paediatric Surveillance unit for rare diseases 
(eSPed; erhebungseinheit für seltene pädiatrische erkrankungen 
in deutschland). data on the reliability of the eSPed tool have 
been published previously.12–14 Briefly, eSPed sends a report card 
to each pediatric department in germany asking pediatricians for 
incident diagnoses with specific inclusion criteria of up to 12 condi-
tions on a monthly basis. each condition is investigated by a prin-
cipal investigator. report cards are to be returned to eSPed even 
if no incident diagnosis is reported. reports of incident diagnoses 
are forwarded to the respective principal investigator. if an incident 
diagnosis is reported, the reporting department is asked to complete 
a questionnaire that is returned to the principal investigator to col-
lect the relevant data. the current return rate of the report cards to 
eSPed is more than 95%.15 Between april 2009 and March 2011, 
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vsrVds were collected on the monthly report cards. the case defi-
nition was patient 0–16 years of age, detection of rV in feces and 
a very severe course of rV disease defined by 1 or more of the 
following criteria: intensive care treatment, hypernatremia >155 
mmol/l, hyponatremia <125 mmol/l, clinical signs of encepha-
lopathy (somnolence, seizures and apneas) and death due to com-
plications related to rV disease.
Patients with a nosocomial rV disease already in intensive 
care treatment were also included because the underlying diseases 
for admission to the intensive care unit (iCu) might increase the 
severity of the rV disease. Once a case was reported, an anonymous 
questionnaire was sent to the reporting clinic and an anonymized 
medical discharge report was asked for. through the question-
naires, basic demographic data were acquired in addition to data 
related to rV disease such as preadmission duration of symptoms, 
rV vaccine status, clinical and laboratory findings, therapy, dura-
tion of hospital stay and health status on discharge. rV disease 
was classified as nosocomial infection if onset of rV symptoms 
occurred more than 48 hours after hospital admission.1
the population number of children and adolescents between 
0 and 16 years of age in germany was 12,636,179 and 12,515,138 
in 2009 and 2010, respectively, adding up to a total of 25,151,317 
of whom 6,818,728 were less than 5 years of age and 2,701,794 
were less than 2 years of age (german Federal Statistical Office—
https://www-genesis.destatis.de; accessed april 27 2012). Popula-
tion data for 2011 were not available at the time of data retrieval.
Collected data were continuously entered into libreOffice 
Calc (version 3.4.4). data were imported to and analyzed using r 
(version 2.14.1), a language and environment for statistical com-
puting.16 Medians with interquartile ranges (iQrs: 25–75 percen-
tile), complete ranges and means where appropriate were used for 
descriptive analysis. For comparison of categorical variables Fisher 
exact test was used. For assessing continuous variables, the Mann–
Whitney–Wilcoxon test was applied because parametric nature of 
the variables could not be assumed. Comparison of categorical 
variables with an assumed or estimated probability distribution was 
performed with Pearson χ2 test (goodness of Fit). the Poisson dis-
tribution was used to calculate 95% confidence intervals (Cis) of 
count data. level of significance was set to P < 0.05. the study 
protocol was approved by the ethics committee of the university of 
essen, essen, germany.
RESULTS
Between april 2009 and March 2011, 130 cases of vsrVd 
were reported. a completed questionnaire or written or oral 
feedback could not be retrieved in 10 cases despite multiple enquir-
ies, yielding a questionnaire return rate of 92%. after deducting 
reports of patients not fulfilling the inclusion criteria (18 reports) 
and 1 double report, 101 cases were evaluable from 58 different 
pediatric departments in germany. the majority of reports (96/101; 
96%) concerned children less than 5 years of age. there were 17 
nosocomial and 84 community-acquired vsrVd, none of which had 
occurred in a child who had received an rV vaccine.
Incidence
to estimate the yearly incidence of vsrVd with a 95% Ci, 
only community-acquired cases were taken into account as the 
reports of nosocomial disease cannot be regarded as independent 
occurrences (eg, multiple cases within 1 clinic). there were 79 
reports of community-acquired vsrVd in children under the age 
of 5 years yielding an incidence of 1.2/100,000/year in children 
less than 5 years of age; 95% Ci: 0.9–1.4/100,000. Considering 
patients less than 2 years of age with a community-acquired dis-
ease (65 patients), the yearly incidence was 2.4/100,000/year; 
95% Ci: 1.9–3.1/100,000.
Seasonal Variation
the monthly incidence of vsrVd varied in parallel to the 
total number of reported rV infections in children less than 14 years 
of age reported to the robert Koch institute as seen in Figure 1. 
Yearly peak incidences were observed in the months March–May.
Nosocomial vsRVd
Seventeen of the 101 cases (17%) were nosocomially 
acquired, of which 16 patients needed or were already in intensive 
care treatment during onset of rV symptoms. One child, a 4-month-
old boy, was reported due to hypernatremia >155 mmol/l.
Fourteen patients were neonates in intensive care treatment. 
three neonates were reported to have apneas as a sign of encepha-
lopathy. a total of 8 neonates were diagnosed with necrotizing 
enterocolitis (neC); in addition, neC was suspected in 4 neonates 
who were treated with antibiotics and withdrawal of enteral nutri-
tion. there was a significant male preponderance (13/17; P = 0.03).
Seven of the 16 neonates were reported by a single hospital 
between July and October 2009; 6 were preterm neonates (29–34 
weeks of gestation) diagnosed with neC and detection of both 
rV and adenovirus in feces. additionally, this hospital reported 
a 2-month-old infant with tetralogy of Fallot and pyloric stenosis 
already in the iCu at the onset of rV disease.
among the 17 reported nosocomial cases 1 death occurred—
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a bilateral third-degree intraventricular hemorrhage with second-
ary hydrocephalus, which was treated with a rickham reservoir. 
additionally, the boy needed a surgical intervention due to a patent 
ductus arteriosus. after these procedures, he was in a stable condi-
tion. However, at the age of 2 months, he showed a rapid clini-
cal deterioration with a suspected neC and clinical and laboratory 
signs of septic shock (C-reactive protein, 107 mg/l; interleukin-6 
>1000 pg/ml), although no bacteria could be isolated in the cer-
ebrospinal fluid (CSF) or blood cultures. the CSF contained 98 
leukocytes/ml.
Community-acquired vsRVd
a total of 84 community-acquired cases were reported (45 
male, 39 female). the median age was 10.5 months (iQr: 4.8–
21.3 months; range: 0–109 months). the median preadmission 
duration of symptoms was 48 hours (iQr: 23.5–72 hours; range: 
0– 168 hours) and the median duration of hospital stay was 6 
days (iQr: 5–11 days; range: 1–85 days). there were no relevant 
gender differences regarding patient age, preadmission duration 
of symptoms or duration of hospital stay. Seventy-nine of the 84 
patients (94%) were less than 5 years of age. the incidence in 
children less than 5 years of age in the various federal states ranged 
from 0 to 2.3/100,000/year. the characteristics of the patients 
grouped by inclusion criteria are shown in table 1. the 2 oldest 
patients were a 8.6-year-old boy with a short bowel syndrome and 
need for total parenteral nutrition being admitted to the iCu due 
to gastrointestinal hemorrhage and a 9-year-old girl with an rV 
encephalitis without any known prior conditions.
Intensive Care Treatment
Forty-eight of the 84 patients (57%) needed treatment in 
an iCu, and their median age (7 months) was significantly lower 
than those who were not admitted to the iCu (median age, 12.5 
months; P = 0.01). the hospital stay was significantly longer if the 
patient needed treatment in an iCu (median, 8.5 days versus 5 days 
in patients not treated in an iCu; P < 0.001).
Electrolyte Disturbances
in 26 of 84 (31%) patients hypernatremia (>155 mmol/l) 
was observed, and 10 (12%) patients had severe hyponatremia 
(<125 mmol/l). Patients with severe hypernatremia tended to be 
younger (median age, 8 months) compared with all other patients 
(median age, 12 months; P = 0.08). Further details are listed in 
table 1.
Encephalopathies
a total of 58 of 84 (69%) patients had clinical signs of 
encephalopathy as defined by the inclusion criteria. Somnolence 
was reported in 44 patients. Five patients had apneas. twenty-three 
patients suffered convulsions (multiple criteria for encephalopathy 
per patient possible). Most convulsions were associated with fever. 
However, 5 of the seizures were afebrile and not associated with 
severe electrolyte disturbance or severe dehydration. Six of the 23 
patients with convulsions also had very severe hypernatremia or 
hyponatremia (n = 2 and n = 4, respectively).
Fourteen of the 58 patients with encephalopathy (24%) 
had pathological electroencephalography. in 22 patients (38% of 
the patients with encephalopathy, 61% of patients with convul-
sions), the CSF was examined revealing pathological findings in 
6 patients: 5 patients had pleocytosis and were diagnosed with 
encephalitis. in a 9-year-old girl who had no convulsions but severe 
hyponatremia, somnolence and pathological electroencephalogra-
phy (general deceleration), rV was identified in her CSF contain-
ing 2000 copies/ml of rV. there was no pleocytosis or abnormal 
levels of glucose, protein or lactate. Magnetic resonance imaging 
on the day of admission first showed an increased signal intensity in 
the splenium of the corpus callosum whereas the control magnetic 
resonance imaging results showed signal changes in the cerebellum 
compatible with cerebellitis 5 days later. She was discharged with 
persisting neurologic symptoms. the CSF was tested for rV by 
polymerase chain reaction only in this one case. Of the remaining 
children with encephalopathy, 1 child was discharged with hemi-
paresis after an intraventricular hemorrhage, 1 child had residual 
convulsions and 1 child was discharged with developmental delay, 
although the delay was present before the rV disease. One patient 
was lost to follow-up after he was transferred to another hospital. 
the remaining patients had fully recovered at the time of hospital 
discharge.
Clinical and Laboratory Findings
Severe dehydration (>10% of the body weight) was observed 
in 39 patients; the median age of these patients (8 months) was 
significantly lower than those with a moderate or no dehydration 
(median age, 15.5 months; P = 0.04). a synopsis of the laboratory 
findings is shown in table 2. Fourteen of the 39 patients (36%) 
with severe dehydration also presented with severe hypernatremia 
(>155 mmol/l); 6 of 39 patients (15%) had severe hyponatremia 
(<125 mmol/l).
Demographic Data
ethnicity-based data of the patients were obtained in 68 of 
the 84 reports of ambulatory-acquired rV disease. Fifty-four of the 
68 patients (79%) were Caucasians from Central europe.
Natural History and Deaths
Seventy-one of the 84 patients (94%) with community-
acquired rV disease were classified as healthy at the time of 
discharge, 3 patients had residual gastrointestinal symptoms, 4 
patients had persisting neurologic symptoms and 1 patient was dis-
charged with a joint effusion, which was associated with a coinfec-
tion caused by Staphylococcus aureus. discharge data were miss-
ing from 2 patients.
TABLE 1. Descriptive Characteristics of the Patients With Community-acquired vsRVd Grouped by Inclusion 
Criteria (Multiple Entries per Patient Possible)
Total cohort ICU Hypernatremia  (>155 mmol/L)
Hyponatremia  
(<125 mmol/L)
Clinical signs of  
encephalopathy
n 84 48 26 10 58
n, male (%) 45 29 (60) 13 (50) 5 (50) 31 (53)
Median age (mo) 10.5 7 7 17.5 10.5
Median preadmission duration of symptoms (h) 48 24 48 30 36
Median duration of hospitalization (days) 6 8.5 6 6.5 6
There was no significant statistical difference between median age and hypernatremia (P = 0.09) or hyponatremia (P = 0.12) compared with the median age of the patients 
without severe electrolyte disturbances.
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However, 5 of the seizures were afebrile and not associated with 
severe electrolyte disturbance or severe dehydration. Six of the 23 
patients with convulsions also had very severe hypernatremia or 
hyponatremia (n = 2 and n = 4, respectively).
Fourteen of the 58 patients with encephalopathy (24%) 
had pathological electroencephalography. in 22 patients (38% of 
the patients with encephalopathy, 61% of patients with convul-
sions), the CSF was examined revealing pathological findings in 
6 patients: 5 patients had pleocytosis and were diagnosed with 
encephalitis. in a 9-year-old girl who had no convulsions but severe 
hyponatremia, somnolence and pathological electroencephalogra-
phy (general deceleration), rV was identified in her CSF contain-
ing 2000 copies/ml of rV. there was no pleocytosis or abnormal 
levels of glucose, protein or lactate. Magnetic resonance imaging 
on the day of admission first showed an increased signal intensity in 
the splenium of the corpus callosum whereas the control magnetic 
resonance imaging results showed signal changes in the cerebellum 
compatible with cerebellitis 5 days later. She was discharged with 
persisting neurologic symptoms. the CSF was tested for rV by 
polymerase chain reaction only in this one case. Of the remaining 
children with encephalopathy, 1 child was discharged with hemi-
paresis after an intraventricular hemorrhage, 1 child had residual 
convulsions and 1 child was discharged with developmental delay, 
although the delay was present before the rV disease. One patient 
was lost to follow-up after he was transferred to another hospital. 
the remaining patients had fully recovered at the time of hospital 
discharge.
Clinical and Laboratory Findings
Severe dehydration (>10% of the body weight) was observed 
in 39 patients; the median age of these patients (8 months) was 
significantly lower than those with a moderate or no dehydration 
(median age, 15.5 months; P = 0.04). a synopsis of the laboratory 
findings is shown in table 2. Fourteen of the 39 patients (36%) 
with severe dehydration also presented with severe hypernatremia 
(>155 mmol/l); 6 of 39 patients (15%) had severe hyponatremia 
(<125 mmol/l).
Demographic Data
ethnicity-based data of the patients were obtained in 68 of 
the 84 reports of ambulatory-acquired rV disease. Fifty-four of the 
68 patients (79%) were Caucasians from Central europe.
Natural History and Deaths
Seventy-one of the 84 patients (94%) with community-
acquired rV disease were classified as healthy at the time of 
discharge, 3 patients had residual gastrointestinal symptoms, 4 
patients had persisting neurologic symptoms and 1 patient was dis-
charged with a joint effusion, which was associated with a coinfec-
tion caused by Staphylococcus aureus. discharge data were miss-
ing from 2 patients.
two deaths among the community-acquired vsrVd were 
reported. a 6-month-old infant with trisomy 21 with diarrhea 
beginning on the day of admission with fever and hyponatremia 
(124 mmol/l). rV and clostridium difficile toxin were identified 
in the stools. Hirschsprung disease was diagnosed during the acute 
exacerbation. the child died due to cardiac and respiratory failure 
and presumed septic shock, although the blood and CSF cultures 
were sterile.
a 12-month-old boy with symptoms of ge beginning 48 
hours before hospital admission with severe dehydration (>10% 
of the body weight) was admitted to the iCu during cardiopulmo-
nary resuscitation. Maximum therapy with parenteral rehydration, 
mechanical ventilation and catecholamines was initiated but the 
boy died on the day of admission due to hypovolemic shock. the 
autopsy revealed no further or concomitant causes.
DISCUSSION
We present a 2-year prospective survey of vsrVd in chil-
dren in germany. Our estimation of the incidence of vsrVd is 
1.2/100,000 in children less than 5 years of age. this estimate is 
a minimum. the true incidence might be twice as high because 
eSPed does not capture all cases as shown by capture–recapture 
analyses.17,18 Comparing this incidence with the overall reported 
incidence of rV disease in the same age group in germany 
(115/10,000),1 a vsrVd occurs in about 1% of all reported rV cases 
in children under 5 years of age.19 the median duration of hospitali-
zation (6 days) is considerably longer than the median duration of 
all reported hospitalized rV cases (2–3 days).1
a recent retrospective analysis of the epidemiology of rV 
infections in children less than 5 years of age in germany describ-
ing the burden of disease was recently published by Koch and 
Wiese-Posselt.1 this publication shows a detailed, descriptive anal-
ysis of national rV surveillance data collected in germany between 
2001 and 2008. although epidemiologic data of hospitalizations 
and numbers of deaths are described in detail, the cases of vsrVd 
are not described or listed. the rV mortality rate we observed fits 
the data of this study that reported 8 deaths in children less than 5 
years of age between 2004 and 2008. another study estimated a 
death rate due to rV infections of 13 per year in children under the 
age of 5 years in germany.4
nosocomial rV infections cause a high disease burden.20–23 
in particular, neonates are prone to severe illness. We observed 14 
neonates treated in an iCu. there were significantly more male 
neonates with nosocomial vsrVd. Male preterm neonates had more 
complications and a poorer outcome than their female counter-
parts.24 this association may explain why male patients dominated 
this group.
rV in neonatal iCus is a well-known problem, especially so, 
as the clinical signs in preterm neonates differ greatly from those 
in older children.25 in particular, diarrhea may not be the leading 
symptom.26,27 Most of the 14 neonates with nosocomially acquired 
rV disease (86%) were diagnosed with or had a suspected neC. 
it has been reported that about 30% of neC cases in preterm neo-
nates are associated with rV.28 the pathogenesis of this association 
remains unclear. it has been hypothesized that a viral nonstructural 
protein evokes abnormal intracellular calcium mobilization in 
enterocytes.29 there was a cluster of 6 neonates with neC excreting 
rV and adenovirus reported by a single hospital over a period of 4 
months. in that hospital, of course, nosocomial rV infection added 
seriously to the common neonatal pathology.25 three neonates were 
reported to have apneas. although this might be a clinical sign of 
encephalopathy, there were no data to distinguish the rV-associated 
apneas from apneas due to prematurity.
ninety-four percent of patients with community-acquired 
rV disease were less than 5 years old. this is in accordance to epi-
demiologic findings in germany and europe.1,30
the overall median duration of admission was 6 days, which 
is considerably longer than the overall hospitalization duration of 
all acquired rV infections in children less than 5 years of age in 
germany (2–3 days).1
the majority of patients with community-acquired vsrVd 
(69%) had clinical signs of encephalopathy. the direct role of rV 
in these cases is not clear because neurologic symptoms may be 
unspecific and related to fever, dehydration or electrolyte distur-
bances. However, in 6 of these patients there was no severe dehy-
dration, electrolyte disturbance or fever reported. Five children had 
afebrile seizures. One of them was coexcreting adenovirus, hav-
ing severe hyponatremia at the time of admission as well. afebrile 
convulsion associated with rV ge has been described numerous 
times.31–34
although patients with rV ge and convulsions were 
included in this study, convulsions in patients with ge generally 
have a good prognosis.35 thus, in most cases excessive diagnostic 
measures and therapeutic attempts can be avoided.36,37 Moreover, 
convulsions in case of ge are not a feature unique to rV. there are 
reports of other pathogens such as norovirus that are the primary 
cause of this clinical feature.38
the CSF was tested for rV only in 1 patient, containing 
2000 copies/ml. the cranial magnetic resonance imaging of this 
patient showed signal intensity alterations in the cerebellum which 
appears to be a recurrent finding in patients with rV-associated 
cerebellitis.39,40
although the detection of rV in the CSF of patients with 
rV-associated encephalopathy may have no direct therapeutic or 
prognostic value, it should be considered if a lumbar puncture is 
performed due to other reasons because this might improve our 
understanding of the rV.
Severe hypernatremia >155 mmol/l was observed in 26 
patients. a recent retrospective study from germany showed a sig-
nificantly higher proportion of children with rV ge with hyperna-
tremia >150 mmol/l compared with rV negative ge cases, propos-
ing hypernatremia to be a particular feature of rV.11 another analysis 
from Sweden showed a hypernatremia in more than 9% of rV ge 
TABLE 2. Descriptive Characteristics of the Laboratory Findings
WBC (/nL) CRP (mg/L) pH BE (mmol/L) pCO2 (mm Hg) Bicarb.(mmol/L) ALT (U/L)
Range 0.4 to 39.5 0 to 443 6.77 to 7.53 −28.3 to 5.2 2.48 to 59.0 6.0 to 30.5 4 to 1364
IQR 6.7 to 16.2 3 to 23.5 7.18 to 7.33 −16.1 to −7.9 24.8 to 35.4 12.0 to 17.3 30 to 81
Median 10.3 8.9 7.27 −12.0 28.4 14.9 43
Mean 12.3 27.9 7.24 −12.0 28.8 14.8 123
WBC indicates white blood cell count (normal values (×1000): less than 2 years of age: 6.5–15.0, 2–6 years 5.0–12.0, 6–16 years 4.5–10.5); CRP, C-reactive protein (normal 
values <5 mg/L); BE, base excess (normal values −2 to +3 mmol/L), pCO2, partial pressure of carbon dioxide (normal values 35–45 mm Hg), Bicarb., bicarbonate (normal values 
21–26 mmol/L); ALT, alanine transaminase (normal values age 0–30 days <90 U/L, 1–12 months < 80 U/L, 1–12 years <50 U/L, 12–16 years <30 U/L). (Normal values from Thomas, 
L.; Labor und Diagnose: Indikation und Bewertung von Laborbefunden für die medizinische Diagnostik, 7th ed., Frankfurt: TH Books-Verlags-Geschellschaft, 2008.)
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cases over a period of 11 years.41 the alanine transaminase was nor-
mal or slightly elevated in most cases. there have been observations 
of rV causing a moderate elevation of liver transaminase.42,43
rV vaccination is currently not generally recommended 
in germany. However, health authorities of each federal state can 
establish local vaccination recommendations. in 5 federal states in 
germany, the rV vaccine has been implemented in their local vacci-
nation program (Saxony, thuringia, Mecklenburg-Western Pomera-
nia, Brandenburg and Schleswig-Holstein). in these states, the cov-
erage is almost 60% as opposed to 20% in the 11 remaining federal 
states.44 there has been a significant drop in rV notifications in 
2010 compared with 2006 in states with a high rV vaccination cov-
erage.44 estimates show that a 90% rV vaccination coverage would 
significantly decrease disease burden in european regions.45,46 it has 
also been suggested that an rV vaccination coverage rate of about 
90% might induce herd immunity, which may play a vital role in 
reducing the number of nosocomially acquired rV diseases..47,48
a limitation of this study is that the survey began after the 
new rV vaccine was approved. as some federal states have already 
implemented the rV vaccine in their local vaccine recommenda-
tions, this may have caused a reduction in the number of vsrVd as 
the rV vaccine reduces the rate of rV hospitalizations.49
as detailed population data for 2011 were not available 
at the time of data retrieval from the german Federal Statistical 
Office, the estimation of incidence may be slightly inaccurate. no 
stool samples were collected to determine the rV serotype, as this 
might have increased the understanding of the rV virulence. it 
has been suggested that disease severity might vary with rV sero-
type.50 rV antigenemia might be observed during an acute rV ge 
as well as in asymptomatic children.51–53 analysis of the patient 
serum might have contributed to determine the role of rV anti-
genemia in courses of vsrVd. Furthermore, a long-term follow-up 
of the patients might have given insight to the long-term effects 
of vsrVd.
even in a country with guaranteed medical care for all and 
a high standard of pediatric care, vsrVd does occur. although rare, 
vsrVd constitutes a considerable burden to the healthcare system 
and the families of the affected children.
Conclusion
Over a period of 2 years, 101 cases of vsrVd in germany 
were reported. although the incidence is relatively low compared 
with all rV cases, significant rV morbidity could be identified in 
a country with free access to health care for all and a highly devel-
oped healthcare system.
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